hrp0092p3-270 | Late Breaking Abstracts | ESPE2019

A Real World, Clinical Experience of Burosumab Therapy in a Cohort of Children with X-Linked Hypophosphataemia

Sandy Jessica , Gilbey-Cross Robyn , Santos Rui , Cocca Alessandra , Sakka Sophia , Morris Mavali , Massey Jill , Cheung Moira

Burosumab, a monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We explored the effects of this treatment in a clinical setting, considering biochemistry, growth, deformity, functionality, quality of life, pain and fatigue.Methods: Clinical, biochemical, radiological and questionnaire data were reviewed at 6 and 12 months in a cohort of 8 children...

hrp0092p1-234 | Growth and Syndromes (to include Turner Syndrome) (1) | ESPE2019

Identification of Syndromal Macrosomia: Macrocephaly, but Neither Height Nor Weight Data are Useful in the Detection of Pediatric PTEN Hamartoma Tumor Syndrome (PHTS)

Plamper Michaela , Gohlke Bettina , Schreiner Felix , Wölfle Joachim

Background: PTEN Hamartoma Tumor Syndrome (PHTS) encompasses different syndromic disorders which are associated with autosomal-dominant mutations of the tumor suppressor gene PTEN. Patients are at high risk to develop benign and malignant tumors. Macrocephaly is a diagnostic feature, but there is a paucity of data on prevalence, degree und development during growth. Charts for length, weight and head circumference for this rare disorder do no...

hrp0089p2-p255 | Growth & Syndromes P2 | ESPE2018

Clinical and Cost-Effectiveness of GH Treatment for Children in Wales

Pop Raluca-Monica , Warner Justin T. , Gregory John W.

Background: GH treatment has been used for the last 30 years for children with short stature with varying individual responses.Objective: Analysis of final height SDS (standard deviation score) and the factors influencing it in children treated with growth hormone.Material and methods: Subjects across Wales who received GH treatment, part supervised by tertiary center staff and reached final height while on treatment, were identifi...

hrp0084fc11.4 | Neuroendocrinology | ESPE2015

Idiopathic Multiple Pituitary Hormone Deficiency (IMPHD): Radiological and Perinatal Factors

Ginige Nimasari , Kirk Jeremy M W , MacPherson Lesley K R

Background: Most cases of multiple pituitary hormone deficiency (MPHD) are acquired and genetic aetiology is rare in the UK. We have investigated whether environmental factors are implicated in ‘idiopathic’ MPHD (IMPHD).Objective and hypotheses: In IMPHD to determine perinatal risk factors and radiological features; to identify the regional epidemiology.Method: Systematic analysis of paediatric IMPHD cases in the UK West ...

hrp0084p3-592 | Adrenals | ESPE2015

Atypical Prednisone-Metabolism: Pharmacological Studies in a Boy with Classical Adrenal Hyperplasia and Suspected Malcompliance

Hess Melanie , Derungs Adrian , Zumsteg Urs W , Szinnai Gabor

Background: We present a boy with classical adrenal hyperplasia (CAH) and constantly increased 17-OH-progesterone (17-OH-P) values despite multiple dose adjustments of hydrocortisone up to 18 mg/m2 body surface and addition of fludrocortisone. After puberty, therapy was changed from hydrocortisone to prednisone without improvement of the 17-OH-P values. Non-compliance was suspected as cause of the inadequately controlled CAH. Alternatively, an atypical steroid metab...

hrp0084p3-790 | DSD | ESPE2015

Evaluation of Two New Anti-Müllerian Hormone Assays for the Investigation of Disorders of Sexual Development in Neonates

Ho Clement K M , Setoh Johnson W S

Background: Anti-Müllerian hormone (AMH) inhibits the in utero growth of the Müllerian structures in female fetuses. In neonates with suspected disorders of sexual development (DSDs), the presence of testicular tissues and functioning Sertoli cells can be investigated by testing for serum AMH concentration.Objective: To evaluate the performance of two new AMH assays in a hospital laboratory.Method: The technical performan...

hrp0094p2-247 | Growth hormone and IGFs | ESPE2021

A girl with concurrent congenital adrenal hyperplasia, isolated growth hormone deficiency type II (IGHD II) and a new mutation in the GH 1 gene – an extremely unusual case

Genthner N , Blum W , Kamrath C , Wudy SA ,

Background: Classical salt wasting congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare disorder, as is isolated growth hormone (GH) deficiency Type II (IGHD II) due to mutation of the growth hormone gene GH1. Here we describe the unusual case of a girl with concurrent 21OHD and IGHD II and its complex diagnostic work up. A 15.3-year-old girl presented with classical salt wasting CAH due to 21OHD and short stature (height 148...

hrp0095p1-493 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Families' Experiences of Continuous Glucose Monitoring in The Management of Congenital Hyperinsulinism: A Thematic Analysis

Auckburally Sameera , Worth Chris , Salomon-Estebanez Maria , Nicholson Jacqueline , Harper Simon , W Nutter Paul , Banerjee Indraneel

Background and Aims: In patients with congenital hyperinsulinism (CHI), recurrent hypoglycaemia can lead to longstanding neurological impairments. At present, glycaemic monitoring is with infrequent fingerprick tests; a practice which can miss hypoglycaemic episodes between tests. Continuous glucose monitoring (CGM) is a promising alternative method which has the utility to identify risk and patterns of hypoglycaemia. Although CGM is well established in type 1...

hrp0092p1-370 | GH and IGFs (2) | ESPE2019

Challenges Experienced in Delivering Growth Hormone Therapy in Children's with Prader Willi Syndrome in Birmingham Children's Hospital.

Kollurage D Udeni Anuruddhika , Barrett Tim , Jayamanne B D W , Krone Ruth

Prader Willi Syndrome (PWS) is a rare neuro-genetic disorder inherited as a result of lack of expression in 15q11-13 gene and 70% are paternally inherited. Characteristic features are dysmorphism, behavioural problems, infantile hypotonia, short stature, hypothalamic dysfunction, hyperphagia and morbid obesity. The long-term morbidity and mortality depend on hypothalamic dysfunction and obesity. While multidisciplinary care is essential, growth hormone (GH) is a recognized...

hrp0092p3-279 | Late Breaking Abstracts | ESPE2019

Relation between Levels of Atymullerian Hormone and Inhibin B and Spontaneous Puberty in Patients with Turner Syndrome – Preliminary Results

Ruszała Anna , Wójcik Małgorzata , Starzyk Jerzy B.

Introduction: Primary hypogonadism is stated as one of major features in patients with Turner Syndrome (TS), however it is not a constant finding. Variable markers of ovaries failure in TS patients are still missing. The present study aimed to evaluate the usefulness of atymullerian hormone and inhibin B assessment in predicting spontaneous puberty in patients with TS.Methods: The study included 35 TS patients. Gonadal a...